Longeveron Secures Patent for Treating Female Sexual Dysfunction
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 17 2025
0mins
Should l Buy LGVN?
Source: Globenewswire
- Patent Grant: Longeveron has been granted a patent by the USPTO covering the use of its proprietary mesenchymal stem cells (MSCs) for treating female sexual dysfunction, with rights extending to 2038, thereby enhancing the company's competitive edge in regenerative medicine.
- Market Demand: Female sexual dysfunction affects up to 46% of women and becomes increasingly common with age, indicating a significant unmet medical need that Longeveron's treatment could address, potentially capturing a growing market.
- Commercialization Prospects: The company anticipates entering into licensing or partnership agreements to advance the development and commercialization of its stem cell therapy, which is expected to create new revenue streams and market opportunities.
- Technological Advantage: Longeveron's laromestrocel (LOMECEL-B®) product is derived from bone marrow cells of young healthy adults and may exhibit multiple mechanisms of action, including anti-inflammatory and regenerative effects, making it applicable to various rare and aging-related diseases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LGVN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LGVN
Wall Street analysts forecast LGVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LGVN is 3.50 USD with a low forecast of 3.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.511
Low
3.00
Averages
3.50
High
4.00
Current: 0.511
Low
3.00
Averages
3.50
High
4.00
About LGVN
Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The Company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pediatric Priority Review Voucher Program Reauthorized
- Incentives for Pediatric Drug Development: The U.S. Congress has passed the Mikaela Naylon Give Kids a Chance Act, reauthorizing the Pediatric Priority Review Voucher Program, which is expected to stimulate the development of innovative drugs for rare pediatric diseases.
- Recognition for Longeveron's Program: Longeveron's laromestrocel program has received three significant FDA designations—Rare Pediatric Disease, Orphan Drug, and Fast Track—indicating its potential in treating Hypoplastic Left Heart Syndrome (HLHS) and possibly improving survival rates for affected children.
- Clinical Trial Progress: Longeveron's ELPIS II clinical trial is underway, having enrolled 40 pediatric patients, with top-line results anticipated in Q3 2026; if positive, the company plans to submit a Biological License Application, further advancing HLHS treatment to market.
- Significant Market Potential: Since August 2024, Priority Review Vouchers have sold for between $150 million and $200 million, highlighting the economic appeal of the program to pharmaceutical companies and potentially attracting more firms to engage in pediatric disease treatment research.
See More
Longeveron Secures Japanese Patent for Stem Cell Therapy Assays
- Patent Grant: The Japan Patent Office has granted Longeveron a patent covering potency assay methods for assessing human mesenchymal stem cells derived from various tissues, securing patent rights in Japan until 2041, thereby enhancing the protection of its clinical programs.
- Clinical Trial Progress: Longeveron's proprietary mesenchymal stem cell therapy, laromestrocel, has shown positive initial results across five clinical trials in three indications, demonstrating its potential in treating rare and aging-related diseases, which further solidifies its market position.
- Global Patent Portfolio Expansion: This patent issuance brings Longeveron's global intellectual property portfolio to 33 patents, reflecting the company's innovative capabilities in cell therapy and enhancing its competitive edge, potentially attracting more investor interest.
- Future Development Plans: Longeveron is conducting a pivotal Phase 2b clinical trial for HLHS, with results expected in Q3 2026, which may lay the groundwork for a Biologics License Application (BLA) with the FDA, further advancing its product commercialization efforts.
See More
Longeveron Joins JPM Healthcare Week to Focus on Alzheimer's Disease
- Participation in Healthcare Summit: Longeveron will participate in the StartUp Health Alzheimer’s & Brain Health Moonshot during JPM Healthcare Week in January 2026, aiming to accelerate breakthroughs in Alzheimer’s and Parkinson’s diseases, showcasing its leadership in the biotechnology sector.
- Investor Meeting Arrangements: The company will host meetings with institutional investors and potential partners during the event, aiming to foster connections that could drive future funding and collaboration opportunities, thereby enhancing market confidence.
- Product Development Progress: Longeveron’s lead product, laromestrocel (LOMECEL-B®), is under development for multiple diseases including Alzheimer’s, having received five significant FDA designations, indicating its potential in clinical stages.
- Strategic Partnerships: By collaborating with the Alzheimer’s Drug Discovery Foundation and Gates Ventures, Longeveron further solidifies its position within the Health Moonshot initiative, demonstrating its commitment to addressing unmet medical needs.
See More
Longeveron Joins Alzheimer's Health Moonshot Initiative During JPM Healthcare Week
- Participation in Health Moonshot: Longeveron will participate in the StartUp Health Alzheimer's & Brain Health Moonshot during JPM Healthcare Week in January 2026, aiming to accelerate breakthroughs in Alzheimer's and Parkinson's diseases, showcasing the company's strategic positioning in neurodegenerative disorders.
- Investor Meeting Arrangements: During this period, Longeveron will host meetings with institutional investors and potential partners, aiming to enhance investor engagement and drive future funding opportunities, reflecting the company's focus on capital markets.
- Product Development Background: Longeveron's lead product, laromestrocel (LOMECEL-B®), is an allogeneic stem cell therapy derived from the bone marrow of young healthy adults, demonstrating multiple potential therapeutic mechanisms and broad applicability across various disease areas.
- FDA Designation Progress: The company has received five significant FDA designations for its product development, including Orphan Drug, Fast Track, and Regenerative Medicine Advanced Therapy, indicating positive regulatory progress and market potential.
See More
Longeveron Secures Patent for Treating Female Sexual Dysfunction
- Patent Grant: Longeveron has secured a patent from the USPTO covering the use of its proprietary mesenchymal stem cells (MSCs) for treating female sexual dysfunction, valid until 2038, which enhances the company's competitive position in this niche market.
- Market Demand: Female sexual dysfunction affects up to 46% of women and becomes increasingly common with age, indicating a significant unmet medical need that Longeveron's treatment could address, thereby capturing a growing market.
- Commercialization Outlook: The company anticipates entering into licensing or partnership agreements to advance the development and commercialization of its stem cell therapy, which is expected to drive future revenue growth, particularly among aging populations.
- R&D Potential: Longeveron's stem cell product, laromestrocel (LOMECEL-B®), exhibits multiple potential mechanisms of action, including anti-inflammatory and regenerative effects, broadening its application prospects across various disease areas.
See More
Longeveron Secures Patent for Treating Female Sexual Dysfunction
- Patent Grant: Longeveron has been granted a patent by the USPTO covering the use of its proprietary mesenchymal stem cells (MSCs) for treating female sexual dysfunction, with rights extending to 2038, thereby enhancing the company's competitive edge in regenerative medicine.
- Market Demand: Female sexual dysfunction affects up to 46% of women and becomes increasingly common with age, indicating a significant unmet medical need that Longeveron's treatment could address, potentially capturing a growing market.
- Commercialization Prospects: The company anticipates entering into licensing or partnership agreements to advance the development and commercialization of its stem cell therapy, which is expected to create new revenue streams and market opportunities.
- Technological Advantage: Longeveron's laromestrocel (LOMECEL-B®) product is derived from bone marrow cells of young healthy adults and may exhibit multiple mechanisms of action, including anti-inflammatory and regenerative effects, making it applicable to various rare and aging-related diseases.
See More
Pediatric Priority Review Voucher Program Reauthorized
- Incentives for Pediatric Drug Development: The U.S. Congress has passed the Mikaela Naylon Give Kids a Chance Act, reauthorizing the Pediatric Priority Review Voucher Program, which is expected to stimulate the development of innovative drugs for rare pediatric diseases.
- Recognition for Longeveron's Program: Longeveron's laromestrocel program has received three significant FDA designations—Rare Pediatric Disease, Orphan Drug, and Fast Track—indicating its potential in treating Hypoplastic Left Heart Syndrome (HLHS) and possibly improving survival rates for affected children.
- Clinical Trial Progress: Longeveron's ELPIS II clinical trial is underway, having enrolled 40 pediatric patients, with top-line results anticipated in Q3 2026; if positive, the company plans to submit a Biological License Application, further advancing HLHS treatment to market.
- Significant Market Potential: Since August 2024, Priority Review Vouchers have sold for between $150 million and $200 million, highlighting the economic appeal of the program to pharmaceutical companies and potentially attracting more firms to engage in pediatric disease treatment research.
See More
Longeveron Secures Japanese Patent for Stem Cell Therapy Assays
- Patent Grant: The Japan Patent Office has granted Longeveron a patent covering potency assay methods for assessing human mesenchymal stem cells derived from various tissues, securing patent rights in Japan until 2041, thereby enhancing the protection of its clinical programs.
- Clinical Trial Progress: Longeveron's proprietary mesenchymal stem cell therapy, laromestrocel, has shown positive initial results across five clinical trials in three indications, demonstrating its potential in treating rare and aging-related diseases, which further solidifies its market position.
- Global Patent Portfolio Expansion: This patent issuance brings Longeveron's global intellectual property portfolio to 33 patents, reflecting the company's innovative capabilities in cell therapy and enhancing its competitive edge, potentially attracting more investor interest.
- Future Development Plans: Longeveron is conducting a pivotal Phase 2b clinical trial for HLHS, with results expected in Q3 2026, which may lay the groundwork for a Biologics License Application (BLA) with the FDA, further advancing its product commercialization efforts.
See More
Longeveron Joins JPM Healthcare Week to Focus on Alzheimer's Disease
- Participation in Healthcare Summit: Longeveron will participate in the StartUp Health Alzheimer’s & Brain Health Moonshot during JPM Healthcare Week in January 2026, aiming to accelerate breakthroughs in Alzheimer’s and Parkinson’s diseases, showcasing its leadership in the biotechnology sector.
- Investor Meeting Arrangements: The company will host meetings with institutional investors and potential partners during the event, aiming to foster connections that could drive future funding and collaboration opportunities, thereby enhancing market confidence.
- Product Development Progress: Longeveron’s lead product, laromestrocel (LOMECEL-B®), is under development for multiple diseases including Alzheimer’s, having received five significant FDA designations, indicating its potential in clinical stages.
- Strategic Partnerships: By collaborating with the Alzheimer’s Drug Discovery Foundation and Gates Ventures, Longeveron further solidifies its position within the Health Moonshot initiative, demonstrating its commitment to addressing unmet medical needs.
See More
Longeveron Joins Alzheimer's Health Moonshot Initiative During JPM Healthcare Week
- Participation in Health Moonshot: Longeveron will participate in the StartUp Health Alzheimer's & Brain Health Moonshot during JPM Healthcare Week in January 2026, aiming to accelerate breakthroughs in Alzheimer's and Parkinson's diseases, showcasing the company's strategic positioning in neurodegenerative disorders.
- Investor Meeting Arrangements: During this period, Longeveron will host meetings with institutional investors and potential partners, aiming to enhance investor engagement and drive future funding opportunities, reflecting the company's focus on capital markets.
- Product Development Background: Longeveron's lead product, laromestrocel (LOMECEL-B®), is an allogeneic stem cell therapy derived from the bone marrow of young healthy adults, demonstrating multiple potential therapeutic mechanisms and broad applicability across various disease areas.
- FDA Designation Progress: The company has received five significant FDA designations for its product development, including Orphan Drug, Fast Track, and Regenerative Medicine Advanced Therapy, indicating positive regulatory progress and market potential.
See More
Longeveron Secures Patent for Treating Female Sexual Dysfunction
- Patent Grant: Longeveron has secured a patent from the USPTO covering the use of its proprietary mesenchymal stem cells (MSCs) for treating female sexual dysfunction, valid until 2038, which enhances the company's competitive position in this niche market.
- Market Demand: Female sexual dysfunction affects up to 46% of women and becomes increasingly common with age, indicating a significant unmet medical need that Longeveron's treatment could address, thereby capturing a growing market.
- Commercialization Outlook: The company anticipates entering into licensing or partnership agreements to advance the development and commercialization of its stem cell therapy, which is expected to drive future revenue growth, particularly among aging populations.
- R&D Potential: Longeveron's stem cell product, laromestrocel (LOMECEL-B®), exhibits multiple potential mechanisms of action, including anti-inflammatory and regenerative effects, broadening its application prospects across various disease areas.
See More
Longeveron Secures Patent for Treating Female Sexual Dysfunction
- Patent Grant: Longeveron has been granted a patent by the USPTO covering the use of its proprietary mesenchymal stem cells (MSCs) for treating female sexual dysfunction, with rights extending to 2038, thereby enhancing the company's competitive edge in regenerative medicine.
- Market Demand: Female sexual dysfunction affects up to 46% of women and becomes increasingly common with age, indicating a significant unmet medical need that Longeveron's treatment could address, potentially capturing a growing market.
- Commercialization Prospects: The company anticipates entering into licensing or partnership agreements to advance the development and commercialization of its stem cell therapy, which is expected to create new revenue streams and market opportunities.
- Technological Advantage: Longeveron's laromestrocel (LOMECEL-B®) product is derived from bone marrow cells of young healthy adults and may exhibit multiple mechanisms of action, including anti-inflammatory and regenerative effects, making it applicable to various rare and aging-related diseases.
See More
